简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
HOME
·
SKB BIO
SKB BIO(06990.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 388.01 million, turned profitable from a loss YoY
Tags：
SKB BIO
06990.HK
turned profitable from loss
2026-08-18
SKB BIO (06990.HK): NMPA Accepts sNDA for Core Product Sac-TMT in First-Line TNBC Treatment
Tags：
SKB BIO
06990.HK
Priority Review
2026-07-30
SKB BIO (06990.HK) plans to issue in total 5.84 million shares by placement, with estimated net proceeds of HKD 2.72 billion
Tags：
SKB BIO
06990.HK
NewTimeSpace
2026-07-08
Featured News
Research
HK Stock Connect Weekly Report: Hang Seng Index Rises 3.55% for the Week; Quarterly Review Results Unveiled, HUA HONG GRACE and ILUVATAR COREX Enter HSI and HSTECH - 20260821
Research
Going Global Weekly Report: Pharma Overseas Expansion Blossoms Across Fronts, A-Share Companies Accelerate Hong Kong Listings - 20260821
Research
HK Stock Connect Daily Report: MINIMAX-W Up Nearly 12%, Z.AI Up Over 10%, Southbound Net Sell of HKD 7.6 Billion - 20260821
Finance
Ingenic Semiconductor (03223.HK): H-Shares Offer Price Set at HK$100 Per Share
Finance
MOBVOI (02438.HK): Expects H1 Loss of RMB 45-58 Million
Finance
FAR INTL (02516.HK): Expects H1 Revenue Up 61%-110% and Turnaround or Narrower Loss
Finance
SHANDONG XINHUA (00719.HK): Obtains Drug Registration Certificate for Dapagliflozin Tablets
Finance
LEADS BIOLABS-B (09887.HK): NDA for Virexin as Treatment for Extrapulmonary Neuroendocrine Carcinoma Accepted by NMPA
Finance
SC HOLDINGS (00413.HK): Expects H1 Net Loss of HKD 400-500 Million
Finance
HK shares ETFs Daily Report: Gold Miners Extend Gains 5.7%! Blockchain and Korea Counterattack in Tandem, Biomedicine and MedTech Lead Declines - 20260821
Scan QR Code
Download App
